Transcatheter Aortic Valve Implantation (TAVI) Market Scope
transcatheter aortic valve implantation (TAVI) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis). Transcatheter aortic valve replacement is sometimes called Transcatheter aortic valve replacement (TAVR). TAVI involves the implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve. The need for transcatheter aortic valve implantation is on the rise due to the increase in the prevalence of aortic stenosis.
The Transcatheter Aortic Valve Implantation (TAVI) market study is segmented by Type (Transfemoral Implantation, Transapical Implantation and Transaortic Implantation), by Application (Hospitals & Clinics and Academic and Research Institutes) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Transcatheter Aortic Valve Implantation (TAVI) market throughout the predicted period.
Boston Scientific (United States), Direct Flow medical (United States), Edwards Lifesciences Corporation (United States), Jenavalve Technology (Germany), Medtronic (Ireland), Meril Life Sciences (India), St. Jude Medical (United States), SYMETIS (Switzerland) and Transcatheter Technologies (Germany) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Transcatheter Aortic Valve Implantation (TAVI) market by Type, Application and Region.
On the basis of geography, the market of Transcatheter Aortic Valve Implantation (TAVI) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In June 2020, Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the Evolut™ Transcatheter Aortic Valve Implantation (TAVI) system for patients with severe native aortic stenosis who are at a low risk of surgical mortality. The Evolut TAVI platform also received a new indication approval that allows for the treatment of patients with bicuspid aortic valves who are at intermediate, high and extreme risk of surgical mortality., and In May 2018, Abbott announced treatment with the company's Portico™ transcatheter aortic valve replacement (TAVR) therapy was associated with excellent clinical outcomes at 30 days, including low rates of death, disabling stroke, and paravalvular leak. Additional benefits observed included a reduction in New York Heart Association (NYHA) class severity, low rates of bleeding, and improvements in a six-minute walk test, allowing patients to return to their previous lifestyles and activity faster.
- Increasing Funding for Research & Development Activities
- Rise in Prevalence of Aortic Stenosis coupled with Increase in Geriatric Population
- Increase in Adoption rate for Transcatheter Aortic Valve Implantation Procedure
- Use of TAVI Systems for New Indications
- Rise in Healthcare Expenditure of Developing countries
- High Cost of the Device and Unfavorable Reimbursement Policies
- Stringent Regulatory Approval Process
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase